SCYNEXIS Inc - ESG Rating & Company Profile powered by AI
The page contains a free ESG assessment covering SCYNEXIS Inc. Comprehensive Sustainability analysis of SCYNEXIS Inc can be accessed by logging in. If you are employed by SCYNEXIS Inc and you wish to use your Sustainability aseessment, please get in touch.
SCYNEXIS Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.1; made up of an environmental score of 2.0, social score of 5.3 and governance score of 4.6.
4.1
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 1376 | Vericel Corp | 4.2 | High |
| 1376 | vTv Therapeutics Inc | 4.2 | High |
| 1412 | SCYNEXIS Inc | 4.1 | High |
| 1412 | Abivax SA | 4.1 | High |
| 1412 | Aeglea Bio Therapeutics Inc | 4.1 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does SCYNEXIS Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes SCYNEXIS Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes SCYNEXIS Inc report the average age of the workforce?
Sign up for free to unlockDoes SCYNEXIS Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes SCYNEXIS Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes SCYNEXIS Inc disclose cybersecurity risks?
Sign up for free to unlockDoes SCYNEXIS Inc offer flexible work?
Sign up for free to unlockDoes SCYNEXIS Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes SCYNEXIS Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes SCYNEXIS Inc conduct supply chain audits?
Sign up for free to unlockDoes SCYNEXIS Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes SCYNEXIS Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes SCYNEXIS Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes SCYNEXIS Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes SCYNEXIS Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes SCYNEXIS Inc disclose water use targets?
Sign up for free to unlockDoes SCYNEXIS Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid SCYNEXIS Inc have a product recall in the last two years?
Sign up for free to unlockDoes SCYNEXIS Inc disclose incidents of discrimination?
Sign up for free to unlockDoes SCYNEXIS Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas SCYNEXIS Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes SCYNEXIS Inc disclose parental leave metrics?
Sign up for free to unlockDoes SCYNEXIS Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes SCYNEXIS Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes SCYNEXIS Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes SCYNEXIS Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes SCYNEXIS Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes SCYNEXIS Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs SCYNEXIS Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes SCYNEXIS Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes SCYNEXIS Inc disclose its waste policy?
Sign up for free to unlockDoes SCYNEXIS Inc report according to TCFD requirements?
Sign up for free to unlockDoes SCYNEXIS Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes SCYNEXIS Inc disclose energy use targets?
Sign up for free to unlockDoes SCYNEXIS Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes SCYNEXIS Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for SCYNEXIS Inc
These potential risks are based on the size, segment and geographies of the company.
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.